(XNCR) Xencor - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 939m USD | Total Return: 47.1% in 12m

Antibodies, Biologics, Immuno-oncology
Total Rating 35
Safety 37
Buy Signal -0.37
Biotechnology
Industry Rotation: +3.7
Market Cap: 939M
Avg Turnover: 10.2M USD
ATR: 6.56%
Peers RS (IBD): 32.8
Risk 5d forecast
Volatility61.8%
Rel. Tail Risk-10.7%
Reward TTM
Sharpe Ratio0.79
Alpha9.11
Character TTM
Beta1.233
Beta Downside1.224
Drawdowns 3y
Max DD76.59%
CAGR/Max DD-0.32
EPS (Earnings per Share) EPS (Earnings per Share) of XNCR over the last years for every Quarter: "2021-03": -0.04, "2021-06": 0.87, "2021-09": -0.69, "2021-12": 1.21, "2022-03": 0.39, "2022-06": -0.57, "2022-09": -0.55, "2022-12": -0.2, "2023-03": -1.02, "2023-06": -0.37, "2023-09": -0.4, "2023-12": -0.31, "2024-03": -1.11, "2024-06": -1.07, "2024-09": -0.71, "2024-12": -0.62, "2025-03": -0.66, "2025-06": -0.41, "2025-09": -0.08, "2025-12": -0.09,
EPS CAGR: -9.42%
EPS Trend: -10.1%
Last SUE: 1.60
Qual. Beats: 3
Revenue Revenue of XNCR over the last years for every Quarter: 2021-03: 33.965, 2021-06: 67.447, 2021-09: 19.683, 2021-12: 154.015, 2022-03: 85.495, 2022-06: 30.175, 2022-09: 27.299, 2022-12: 21.61, 2023-03: 18.962, 2023-06: 45.523, 2023-09: 59.164, 2023-12: 50.966, 2024-03: 15.997, 2024-06: 16.96, 2024-09: 17.796, 2024-12: 70.018, 2025-03: 32.732, 2025-06: 43.608, 2025-09: 20.999, 2025-12: 28.237,
Rev. CAGR: -25.58%
Rev. Trend: -15.8%
Last SUE: -0.15
Qual. Beats: 0

Warnings

High Debt/EBITDA (7.6) with thin interest coverage (-1.8)

High Debt while negative Cash Flow

Interest Coverage Ratio -1.8 is critical

Altman Z'' -3.09 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: XNCR Xencor

Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical company specializing in engineered monoclonal antibodies. Its pipeline targets asthma, allergic diseases, autoimmune diseases, and various cancers. The biotechnology sector is characterized by high research and development costs and a long drug development timeline, typically 10-15 years from discovery to market.

Xencors strategy involves developing its own drug candidates and partnering with other pharmaceutical companies, leveraging its XmAb Fc technologies. This dual approach allows for both proprietary drug development and licensing revenue. The company has multiple products on the market, including Ultomiris and Monjuvi, and a broad pipeline of drug candidates in various clinical trial phases, from Phase I to Phase II, for diverse conditions such as renal cell carcinoma, ovarian cancer, prostate cancer, Crohns disease, and HIV.

To gain further insights into Xencors financial performance and market position, consider exploring its detailed analytics on ValueRay.

Headlines to Watch Out For
  • Clinical trial outcomes significantly impact future revenue prospects
  • Regulatory approvals for new drug candidates drive market value
  • Partnerships and licensing agreements provide crucial funding and revenue
  • Competition from other biopharmaceutical companies affects market share
  • Research and development expenses are a major cost factor
Piotroski VR‑10 (Strict) 1.0
Net Income: -91.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.16 > 0.02 and ΔFCF/TA 6.66 > 1.0
NWC/Revenue: 401.3% < 20% (prev 405.9%; Δ -4.58% < -1%)
CFO/TA -0.15 > 3% & CFO -135.1m > Net Income -91.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.25 > 1.5 & < 3
Outstanding Shares: last quarter (74.2m) vs 12m ago 1.45% < -2%
Gross Margin: 91.62% > 18% (prev 0.50%; Δ 9.11k% > 0.5%)
Asset Turnover: 13.74% > 50% (prev 12.69%; Δ 1.06% > 0%)
Interest Coverage Ratio: -1.81 > 6 (EBITDA TTM -47.2m / Interest Expense TTM 31.9m)
Altman Z'' -3.09
A: 0.58 (Total Current Assets 599.8m - Total Current Liabilities 95.9m) / Total Assets 875.5m
B: -0.91 (Retained Earnings -796.0m / Total Assets 875.5m)
C: -0.06 (EBIT TTM -57.7m / Avg Total Assets 913.7m)
D: -3.31 (Book Value of Equity -793.7m / Total Liabilities 239.9m)
Altman-Z'' Score: -3.09 = D
Beneish M -3.96
DSRI: 0.46 (Receivables 29.3m/60.8m, Revenue 125.6m/120.8m)
GMI: 0.55 (GM 91.62% / 50.18%)
AQI: 0.73 (AQ_t 0.21 / AQ_t-1 0.29)
SGI: 1.04 (Revenue 125.6m / 120.8m)
TATA: 0.05 (NI -91.9m - CFO -135.1m) / TA 875.5m)
Beneish M-Score: -3.96 (Cap -4..+1) = AAA
What is the price of XNCR shares? As of April 08, 2026, the stock is trading at USD 12.31 with a total of 490,005 shares traded.
Over the past week, the price has changed by +2.07%, over one month by +3.71%, over three months by -17.66% and over the past year by +47.07%.
Is XNCR a buy, sell or hold? Xencor has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XNCR.
  • StrongBuy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the XNCR price?
Analysts Target Price 28.4 130.9%
Xencor (XNCR) - Fundamental Data Overview as of 05 April 2026
P/E Forward = 68.0272
P/S = 7.4813
P/B = 1.4458
Revenue TTM = 125.6m USD
EBIT TTM = -57.7m USD
EBITDA TTM = -47.2m USD
Long Term Debt = 76.5m USD (from longTermDebt, last quarter)
Short Term Debt = 46.5m USD (from shortTermDebt, last quarter)
Debt = 187.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -360.0m USD (recalculated: Debt 187.7m - CCE 547.7m)
Enterprise Value = 579.5m USD (939.5m + Debt 187.7m - CCE 547.7m)
Interest Coverage Ratio = -1.81 (Ebit TTM -57.7m / Interest Expense TTM 31.9m)
EV/FCF = -4.19x (Enterprise Value 579.5m / FCF TTM -138.3m)
FCF Yield = -23.86% (FCF TTM -138.3m / Enterprise Value 579.5m)
 FCF Margin = -110.1% (FCF TTM -138.3m / Revenue TTM 125.6m)
 Net Margin = -73.20% (Net Income TTM -91.9m / Revenue TTM 125.6m)
Gross Margin = 91.62% ((Revenue TTM 125.6m - Cost of Revenue TTM 10.5m) / Revenue TTM)
Gross Margin QoQ = 90.87% (prev 87.62%)
Tobins Q-Ratio = 0.66 (Enterprise Value 579.5m / Total Assets 875.5m)
Interest Expense / Debt = 3.92% (Interest Expense 7.35m / Debt 187.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.6m (EBIT -57.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.25 (Total Current Assets 599.8m / Total Current Liabilities 95.9m)
Debt / Equity = 0.30 (Debt 187.7m / totalStockholderEquity, last quarter 635.6m)
 Debt / EBITDA = 7.63 (negative EBITDA) (Net Debt -360.0m / EBITDA -47.2m)
 Debt / FCF = 2.60 (negative FCF - burning cash) (Net Debt -360.0m / FCF TTM -138.3m)
 Total Stockholder Equity = 630.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.06% (Net Income -91.9m / Total Assets 875.5m)
RoE = -14.58% (Net Income TTM -91.9m / Total Stockholder Equity 630.3m)
RoCE = -8.16% (EBIT -57.7m / Capital Employed (Equity 630.3m + L.T.Debt 76.5m))
 RoIC = -6.90% (negative operating profit) (NOPAT -45.6m / Invested Capital 660.2m)
 WACC = 9.12% (E(939.5m)/V(1.13b) * Re(10.32%) + D(187.7m)/V(1.13b) * Rd(3.92%) * (1-Tc(0.21)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.46%
 [DCF] Fair Price = unknown (Cash Flow -138.3m)
 EPS Correlation: -10.06 | EPS CAGR: -9.42% | SUE: 1.60 | # QB: 3
Revenue Correlation: -15.85 | Revenue CAGR: -25.58% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.76 | Chg7d=-0.024 | Chg30d=-0.121 | Revisions Net=-2 | Analysts=10
EPS current Year (2026-12-31): EPS=-3.08 | Chg7d=-0.102 | Chg30d=-0.457 | Revisions Net=-7 | Growth EPS=-148.2% | Growth Revenue=-6.5%
EPS next Year (2027-12-31): EPS=-2.98 | Chg7d=+0.000 | Chg30d=-0.679 | Revisions Net=-6 | Growth EPS=+3.0% | Growth Revenue=+21.2%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle